It has also been found that Keap1/Nrf2 mutation status predicts the risk of local recurrence after radiotherapy in NSCLC patients, and Keap1/Nrf2 mutant lung cancers may be radiotherapy resistant to radaition due to enhanced expression of ROS clearance and detoxification pathways (Jeong et al., 2017). This evidence concerns the gene KEAP1 and lung cancer.